# FDA 483 - Ahsan A. Abdulghani, M.D. - August 21, 2023

Source: https://www.keypedia.com/records/483/ahsan-a-abdulghani-md/49fd03df-e4ed-4e3f-8e8d-51183cad235d

> FDA 483 for Ahsan A. Abdulghani, M.D. on August 21, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ahsan A. Abdulghani, M.D.
- Inspection Date: 2023-08-21
- Product Type: drugs
- Office Name: New Jersey District Office
- Summary: An FDA inspection of Ahsan A. Abdulghani, M.D. in Turnersville, NJ, revealed significant deficiencies in the conduct of a clinical investigation. Observations included failure to follow the study protocol, maintain accurate and complete case histories, and properly manage investigational drug disposition. These issues raise concerns about data integrity and subject safety during the clinical trial.

## Related Officers

- [investigator](https://www.keypedia.com/people/michael-serrano/44c9d307-9d78-4480-b1d0-36096c056642)

Company: https://www.keypedia.com/companies/ahsan-a-abdulghani-md/695f1bb9-8d1b-4f0c-b158-c5b387d4f232

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248